HUBUNGAN IgA ANTI-VCA EVB DENGAN GAMBARAN HISTOPATOLOGI PADA PENDERITA KARSINOMA NASOFARING
DOI:
https://doi.org/10.24269/ijhs.v4i2.2088Abstract
Karsinoma nasofaring (KNF) merupakan keganasan yang terjadi pada epitel nasofaring. Sebagian besar lokasi penderita KNF terpusat pada benua Asia dan memiliki garis keturunan yang berasal dari Cina bagian Selatan, terutama yang merupakan bagian dari suku Fujian dan Kantonesia. Penggunaan anti-VCA mulai dikenalsebagai salah satu penanda uji tapis. Penelitian ini bertujuan untuk mengetahui hubungan nilai serologi IgA anti-VCA dengan gambaran histopatologi KNF tanpa menilai faktor risiko lainnya. Jenis penelitian yang digunakan berupa analitik observasional dengan desain potong lintang. Sampel diambil secara consecutive sampling dari penderita KNFyang memenuhi kriteria inklusi dan eksklusi sejumlah 33 orang. Hasil penelitian menunjukkan dari 33 sampel, didapati 22 orang sampel berjenis kelamin laki-laki (66,7%), dengan kelompok usia 50-59 tahun sejumlah 12 orang (36,4%) dan 14 orang sampel berprofesi sebagai wiraswasta (42,4%). Sebagian besar sampel memiliki gambaran histopatologi tipe II sebanyak 21 orang (63,6%), tipe III sebanyak 12 orang (36,4%) dan tidak dijumpainya gambaran histopatologi tipe I. Pada pemeriksaan ELISA IgA anti-VCA EBV ditemukan immunoglobulin tersebut pada 22 orang sampel (66,7%). Analisis chi-square menunjukkan hubungan antara nilai serologi IgA anti-VCA EBV dengan gambaran histopatologi KNF dengan nilai p<0,002
Downloads
Download data is not yet available.
References
[1] M.L.K. Chua, J.T.S. Wee, E.P.Hui, and A.T.C. Chan, “Nasopharyngeal carcinoma,†Lancet, vol. 387, pp. 1012-1024, 2016.
[2] N. Lee, N. Riaz, R. Ove, M.L. Reyngold, R.L. Foote, and J.A. Booner, “Nasopharyngeal Carcinoma, 4th ed, Elsevier Inc, 2016.
[3] Kementerian Kesehatan Republik Indonesia.. Kanker Nasofaring. Jakarta. 2017.
[4] W. Melani and F. Sofyan, “Karakteristik penderita kanker nasofaring di Rumah Sakit H.Adam Malik Medan Tahun 2011†E-Jurnal FK USU, vol. 1, 2011.
[5] M. Adham, A.N. Kurniawan, A.I. Muhtadi, A. Roezin, B. Hermani, S. Gonhowiardjo, I.B. Tan, and J.M. Middeldorp, “Nasopharyngeal carcinoma in Indonesia: epidemio-logy, incidence, signs, and symptoms at presentation†Chin J Cancer, vol. 31, pp. 185-96, 2012.
[6] H.P. Li and Y.S. Chang, “Epstein-Barr virus latent membrane protein 1: Structure and functions,†J Biomed Sci, vol. 10, pp.490-504, 2003.
[7] Z.L. Pratt, J. Zhang, and B. Sugden, “The Latent Membrane Protein 1 (LMP1) Oncogene of Epstein-Barr Virus Can Simultaneously Induce and Inhibit Apoptosis in B Cells,â€J Virol, vol. 86, pp. 4380-4393, 2012
[8] K. Moumad, N. Laantri, M. Attaleb, and R. Dardari,“Role of the Epstein-Barr Virus ZEBRA protein and HPV in the Carcinogenesis of naso-pharyngeal carcinoma, carcinogenes-is, diagnosis, and molecular Targeted Treatment for Naso-pharyngeal Carcinoma,â€Dr.Shih-Shun Chen, pp.978-953-307-867-0, 2012.
[9] W.H. Jia and H.D. Qin, “Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic reviewâ€, Semin Cancer Biol, vol. 22, pp.117-126, 2012.
[10] M.S Zeng and Y.X. Zeng “Pathogenesis and Etiology of Nasopharyngeal Carcinoma,†Nasopharyngeal Cancer Multidiscip Manag, pp. 9-25, 2010.
[11] F. Bray, M. Haugen, T.A. Moger, S. Tretti, O.O Aalen, and T. Grotmol, “Age-incidence curves of naso-pharyngeal carcinoma worldwide: bimodality in low-risk populations and etiologic implications,†Cancer Epidemiology and Prevention Bio-markers,vol.17,pp.2356-2365, 2008.
[12] F. Farhat, E.R. Daulay, J. ChrestellaJ, R.A. Asnir, A. Yudhistira, and R.R. Susilo, “Correlation of P38 Mitogen-Activated Protein Kinase Expression to Clinical Stage in Nasopharyngeal Carcinoma, “ Open access Mecodonian journal of medical sciences, vol. 6, pp. 1982-1985. 2018.
[13] M. Kanno, N. Narita, Y. Fujimoto, N. Wakisaka, T. Yoshizaki, T. Kodaira, C. Makita, Y. Sato, K. Yamazaki, T. Wakaoka, Y. Shimode, H. Tsuji, R. Kito, H. Ishinaga, S. Hosokawa, H. Takakura, K. Nishimura, T. Matoba, and S. Fujieda, “Third Epidemio-logical Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015,†Cancers, vol. 11, pp. 1180. 2019.
[14] T. Hu, H.S. Lin, H.S. Xie, H.G. Chen, Q.Y. Lu, W. Ling, H.Q. Huang, Q. Liu, and M.S. Cao, “Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epsteinâ€Barr Virus: An analysis of a prospective study in southern China,†Cancer Medice, vol.8, pp. 2561-2571, 2019.
[15] A.D. Alotaibi, H.G. Ahmed, and A.M. Elasbali “Nasopharyngeal cancer in Saudi Arabia: Epidemiology and possible risk factors,†Journal of Oncological Sciences, vol. 5, pp. 23-30, 2019.
[16] J. Chrestella, F. Farhat, E.R Daulay, R.A. Asnir, A. Yudhistira, and I.A. Nasution, “Cyclooxygenese-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma,†Open access Mecodonian journal of medical sciences, vol. 6, pp. 2001-2005, 2018.
[17] D.D. Suta, D.A. Saputra, and D.W. Sutanegara, “Profil Penderita Kanker Nasoparing di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari - Desember Tahun 2014,†E – Jurnal Medica, vol. 8, 2019.
[18] H. Chen, P. Chi, W. Wang, L. Li, Y. Luo, J. Fu, L. Zhang, and W. Liu, “Evaluation of a semiquantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma,†Int J Infect Dis, vol. 25, pp.110-5, 2014.
[19] S.M. Cao, M.J. Simons, and C.N. Qian, “The prevalence and prevention of nasopharyngeal carcinoma in China,†Chinese journal of cancer, vol. 30, pp.114-9, 2011.
[20] C. Xia, K. Zhu, G. Zheng, “Expression of EBV antibody EA-IgA, Rta-IgG, and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis,†Int J Clin Exp Pathol, vol. 8, pp.16104-16110, 2011.
[21] K.J. Tay, H.S Chan, M.C. Lim, C.H. Siow, H.L. Goh, and K.S. Loh, “The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma,†Otolaryngology-Head and Neck Surgery, vol. 155, pp. 274-280, 2016.
[22] H. Chen, S. Chen, J. Lu, X. Wang, J. Li, L. Li, J. Fu, T. Scheper, W. Meyer, Y.H. Peng YH, and W. Liu, “Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngel Carcinoma in a High-Risk population of China,†Cancer prevention research, vol.10, pp. 542-550, 2017.
[23] Y. Song, H. Xiao, Z. Yang, M. Geng, J. Ma, Y. Ren, “The predictive value of pre‑ and post‑induction chemotherapy plasma EBV DNA level and tumor volume for the radiosensitivity of locally advanced nasopharyngeal carcinoma,†Excli J, vol. 16, pp, 1268‑1275, 2017.
[24] L. Barnes, J.W. Eveson, P. Reichart, and Sidransky, “Pathology and genetic head and neck tumours,†3rd E, vol. 9. New York: IARC Press, 2005.
[25] U. Nurjanah, M.P. Hendrati, B.A. Dharmawan,and ASN Gumilas, “Deteksi Gen Latent Membrane Protein-1 Epstein-Barr Virus Sebagai Biomarka Pada Karsinoma Nasofaring,â€Biosfera, vol. 33, pp. 76-84, 2016.
[26] S. Faiza, R. Sukri, and A. Aswiyanti, “Karakteristik Klinis dan Patologis KNF di Bagian THT-KL RSUP Dr.M.Djamil Padang,†Jurnal Kesehatan Andalas, vol 5, pp. 90-96, 2016.
[27] A.C. Romdhoni, N. Wiqoyah, and W.A. Kentjono, “Early detection of nasopharyngeal carcinoma using IgA anti-EBNA1+ VCA-p18 serology assay,â€Ear, Nose & Throat Journal, vol. 93, pp. 112-115, 2014.
[28] A.W. Lee, B.B. Ma, W.T. Ng, and A.T. Chan, “Management of nasopharyngeal carcinoma: Current practice and future perspective,â€J Clin Oncol, vol. 33, pp. 3356‑3364, 2015.
[2] N. Lee, N. Riaz, R. Ove, M.L. Reyngold, R.L. Foote, and J.A. Booner, “Nasopharyngeal Carcinoma, 4th ed, Elsevier Inc, 2016.
[3] Kementerian Kesehatan Republik Indonesia.. Kanker Nasofaring. Jakarta. 2017.
[4] W. Melani and F. Sofyan, “Karakteristik penderita kanker nasofaring di Rumah Sakit H.Adam Malik Medan Tahun 2011†E-Jurnal FK USU, vol. 1, 2011.
[5] M. Adham, A.N. Kurniawan, A.I. Muhtadi, A. Roezin, B. Hermani, S. Gonhowiardjo, I.B. Tan, and J.M. Middeldorp, “Nasopharyngeal carcinoma in Indonesia: epidemio-logy, incidence, signs, and symptoms at presentation†Chin J Cancer, vol. 31, pp. 185-96, 2012.
[6] H.P. Li and Y.S. Chang, “Epstein-Barr virus latent membrane protein 1: Structure and functions,†J Biomed Sci, vol. 10, pp.490-504, 2003.
[7] Z.L. Pratt, J. Zhang, and B. Sugden, “The Latent Membrane Protein 1 (LMP1) Oncogene of Epstein-Barr Virus Can Simultaneously Induce and Inhibit Apoptosis in B Cells,â€J Virol, vol. 86, pp. 4380-4393, 2012
[8] K. Moumad, N. Laantri, M. Attaleb, and R. Dardari,“Role of the Epstein-Barr Virus ZEBRA protein and HPV in the Carcinogenesis of naso-pharyngeal carcinoma, carcinogenes-is, diagnosis, and molecular Targeted Treatment for Naso-pharyngeal Carcinoma,â€Dr.Shih-Shun Chen, pp.978-953-307-867-0, 2012.
[9] W.H. Jia and H.D. Qin, “Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic reviewâ€, Semin Cancer Biol, vol. 22, pp.117-126, 2012.
[10] M.S Zeng and Y.X. Zeng “Pathogenesis and Etiology of Nasopharyngeal Carcinoma,†Nasopharyngeal Cancer Multidiscip Manag, pp. 9-25, 2010.
[11] F. Bray, M. Haugen, T.A. Moger, S. Tretti, O.O Aalen, and T. Grotmol, “Age-incidence curves of naso-pharyngeal carcinoma worldwide: bimodality in low-risk populations and etiologic implications,†Cancer Epidemiology and Prevention Bio-markers,vol.17,pp.2356-2365, 2008.
[12] F. Farhat, E.R. Daulay, J. ChrestellaJ, R.A. Asnir, A. Yudhistira, and R.R. Susilo, “Correlation of P38 Mitogen-Activated Protein Kinase Expression to Clinical Stage in Nasopharyngeal Carcinoma, “ Open access Mecodonian journal of medical sciences, vol. 6, pp. 1982-1985. 2018.
[13] M. Kanno, N. Narita, Y. Fujimoto, N. Wakisaka, T. Yoshizaki, T. Kodaira, C. Makita, Y. Sato, K. Yamazaki, T. Wakaoka, Y. Shimode, H. Tsuji, R. Kito, H. Ishinaga, S. Hosokawa, H. Takakura, K. Nishimura, T. Matoba, and S. Fujieda, “Third Epidemio-logical Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015,†Cancers, vol. 11, pp. 1180. 2019.
[14] T. Hu, H.S. Lin, H.S. Xie, H.G. Chen, Q.Y. Lu, W. Ling, H.Q. Huang, Q. Liu, and M.S. Cao, “Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epsteinâ€Barr Virus: An analysis of a prospective study in southern China,†Cancer Medice, vol.8, pp. 2561-2571, 2019.
[15] A.D. Alotaibi, H.G. Ahmed, and A.M. Elasbali “Nasopharyngeal cancer in Saudi Arabia: Epidemiology and possible risk factors,†Journal of Oncological Sciences, vol. 5, pp. 23-30, 2019.
[16] J. Chrestella, F. Farhat, E.R Daulay, R.A. Asnir, A. Yudhistira, and I.A. Nasution, “Cyclooxygenese-2 Expression and Its Correlation with Primary Tumor Size and Lymph Node Involvement in Nasopharyngeal Carcinoma,†Open access Mecodonian journal of medical sciences, vol. 6, pp. 2001-2005, 2018.
[17] D.D. Suta, D.A. Saputra, and D.W. Sutanegara, “Profil Penderita Kanker Nasoparing di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari - Desember Tahun 2014,†E – Jurnal Medica, vol. 8, 2019.
[18] H. Chen, P. Chi, W. Wang, L. Li, Y. Luo, J. Fu, L. Zhang, and W. Liu, “Evaluation of a semiquantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma,†Int J Infect Dis, vol. 25, pp.110-5, 2014.
[19] S.M. Cao, M.J. Simons, and C.N. Qian, “The prevalence and prevention of nasopharyngeal carcinoma in China,†Chinese journal of cancer, vol. 30, pp.114-9, 2011.
[20] C. Xia, K. Zhu, G. Zheng, “Expression of EBV antibody EA-IgA, Rta-IgG, and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis,†Int J Clin Exp Pathol, vol. 8, pp.16104-16110, 2011.
[21] K.J. Tay, H.S Chan, M.C. Lim, C.H. Siow, H.L. Goh, and K.S. Loh, “The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma,†Otolaryngology-Head and Neck Surgery, vol. 155, pp. 274-280, 2016.
[22] H. Chen, S. Chen, J. Lu, X. Wang, J. Li, L. Li, J. Fu, T. Scheper, W. Meyer, Y.H. Peng YH, and W. Liu, “Multiparametric Detection of Antibodies against Different EBV Antigens to Predict Risk for Nasopharyngel Carcinoma in a High-Risk population of China,†Cancer prevention research, vol.10, pp. 542-550, 2017.
[23] Y. Song, H. Xiao, Z. Yang, M. Geng, J. Ma, Y. Ren, “The predictive value of pre‑ and post‑induction chemotherapy plasma EBV DNA level and tumor volume for the radiosensitivity of locally advanced nasopharyngeal carcinoma,†Excli J, vol. 16, pp, 1268‑1275, 2017.
[24] L. Barnes, J.W. Eveson, P. Reichart, and Sidransky, “Pathology and genetic head and neck tumours,†3rd E, vol. 9. New York: IARC Press, 2005.
[25] U. Nurjanah, M.P. Hendrati, B.A. Dharmawan,and ASN Gumilas, “Deteksi Gen Latent Membrane Protein-1 Epstein-Barr Virus Sebagai Biomarka Pada Karsinoma Nasofaring,â€Biosfera, vol. 33, pp. 76-84, 2016.
[26] S. Faiza, R. Sukri, and A. Aswiyanti, “Karakteristik Klinis dan Patologis KNF di Bagian THT-KL RSUP Dr.M.Djamil Padang,†Jurnal Kesehatan Andalas, vol 5, pp. 90-96, 2016.
[27] A.C. Romdhoni, N. Wiqoyah, and W.A. Kentjono, “Early detection of nasopharyngeal carcinoma using IgA anti-EBNA1+ VCA-p18 serology assay,â€Ear, Nose & Throat Journal, vol. 93, pp. 112-115, 2014.
[28] A.W. Lee, B.B. Ma, W.T. Ng, and A.T. Chan, “Management of nasopharyngeal carcinoma: Current practice and future perspective,â€J Clin Oncol, vol. 33, pp. 3356‑3364, 2015.
Downloads
Published
2020-09-01
Issue
Section
Artikel
Citation Check
License
Authors who publish with Indonesian Journal for Health Sciences (IJHS) agree to the following terms:
1. Copyright and License
The copyright of articles published in the Indonesian Journal for Health Sciences is transferred to and held by the journal/publisher. Authors agree to transfer the copyright of their accepted articles to the Indonesian Journal for Health Sciences. All published articles are distributed under a Creative Commons Attribution-ShareAlike (CC BY-SA) license. This license allows others to share, adapt, and build upon the work in any medium or format, including for commercial purposes, provided that appropriate credit is given to the original source and that any derivative works are distributed under the same license..
2. Author Rights
Authors are permitted and encouraged to share their work online (e.g., in institutional repositories, personal websites, or academic networking platforms) before and during the submission process, as this can lead to productive academic exchanges and increased citation of the published work. Authors may archive the pre-print, post-print, or publisher’s PDF version of their article with an acknowledgment of its initial publication in Indonesian Journal for Health Sciences.
3. Copyright Transfer Agreement
Indonesian Journal for Health Sciences requires authors to complete and sign a formal Copyright Transfer Agreement (CTA) form before publication. The form confirms that the submitted work is original, has not been published elsewhere, and that all authors agree to transfer the publication rights to the journal for the purpose of dissemination and indexing.
The form can be downloaded here
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
